International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors

Advantages of external quality assessment‐EQA programs

(2022) Silmara Aparecida de Lima Montalvão et al.   HAEMOPHILIA

Methods for anti‐factor VIII antibody levels in haemophilia A patients – validation of a multiplex immunoassay and comparability with assays measuring non‐neutralising and neutralising antibodies (inhibitors)

(2022) Myriam Martin et al.   HAEMOPHILIA

Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey

(2021) Paul Batty et al.   HAEMOPHILIA

The chromogenic Bethesda assay and the Nijmegen‐Bethesda assay for factor VIII inhibitors in hemophilia A patients: Are they equivalent?

(2021) Connie H. Miller et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects

(2020) Emmanuel J. Favaloro et al.   HAEMOPHILIA

WFH Guidelines for the Management of Hemophilia, 3rd edition

(2020) Alok Srivastava et al.   HAEMOPHILIA

Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise

(2020) Anna Lowe et al.   HAEMOPHILIA

Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies: comment

(2019) Hideo Wada et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Heat inactivation of extended half‐life factor VIII concentrates

(2019) Kara A. Fylling et al.   HAEMOPHILIA

Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

(2019) Joanne Adamkewicz et al.   THROMBOSIS AND HAEMOSTASIS

Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A

(2019) Jens Müller et al.   THROMBOSIS AND HAEMOSTASIS

Emicizumab: A Review in Haemophilia A

(2019) Hannah A. Blair   DRUGS

Evaluation of pre‐analytic heat treatment protocol used in the CDC Nijmegen‐Bethesda assay for heat inactivation of extended half‐life haemophilia treatment products

(2019) Amanda B. Payne et al.   HAEMOPHILIA

The effects of transport temperature and time on routine and specialized coagulation assays

(2018) Yeowon A. Kim et al.   BLOOD COAGULATION & FIBRINOLYSIS

Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review

(2018) C. H. Miller   HAEMOPHILIA

Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels

(2018) B. Boylan et al.   HAEMOPHILIA

Reagent substitutions in the Centers for Disease Control and Prevention Nijmegen-Bethesda assay for factor VIII inhibitors

(2018) C. H. Miller et al.   HAEMOPHILIA

Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies

(2018) K. Nogami et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity

(2018) Takehisa Kitazawa et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban

(2018) Sean Platton et al.   International Journal of Laboratory Hematology

Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors

(2017) C. H. Miller et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

(2017) Johannes Oldenburg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lupus anticoagulants associated inhibitor against factor IX in a young patient with haemophilia B

(2016) A. Barnbrock et al.   HAEMOPHILIA

Quality laboratory issues in bleeding disorders

(2016) D. M. Adcock et al.   HAEMOPHILIA

A variation of the Nijmegen-Bethesda assay using heat or a novel heat/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity

(2016) A. H. Millner et al.   International Journal of Laboratory Hematology

Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay

(2016) B. Boylan et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A critical appraisal of one-stage and chromogenic assays of factor VIII activity

(2016) F. Peyvandi et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The past and future of haemophilia: diagnosis, treatments, and its complications

(2016) Flora Peyvandi et al.   LANCET

One-stage vs. chromogenic assays in haemophilia A

(2015) Joachim J. Potgieter et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients

(2015) S. A. L. Montalvão et al.   HAEMOPHILIA

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

(2015) W. Kreuz et al.   HAEMOPHILIA

Pearls and pitfalls in factor inhibitor assays

(2015) D. M. Adcock et al.   International Journal of Laboratory Hematology

The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples

(2015) Roslyn Bonar et al.   PATHOLOGY

Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A

(2015) Paul Batty et al.   THROMBOSIS AND HAEMOSTASIS

Heat treatment of samples improve the performance of the Nijmegen–Bethesda assay in hemophilia A patients undergoing immune tolerance induction

(2015) Silmara Aparecida de Lima Montalvão et al.   THROMBOSIS RESEARCH

Improving the performance of factor VIII inhibitor tests in hemophilia A

(2015) Connie H. Miller   THROMBOSIS RESEARCH

Pre-analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A

(2014) Paul Batty et al.   BRITISH JOURNAL OF HAEMATOLOGY

Laboratory testing for factor inhibitors

(2014) E. J. Favaloro et al.   HAEMOPHILIA

Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?

(2014) C. Pouplard et al.   International Journal of Laboratory Hematology

Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay

(2014) B. Boylan et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Definitions in hemophilia: communication from the SSC of the ISTH

(2014) V. S. Blanchette et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Rituximab for treatment of inhibitors in haemophilia A

(2014) Cindy Leissinger et al.   THROMBOSIS AND HAEMOSTASIS

Performance of coagulation tests in patients on therapeutic doses of rivaroxaban

(2014) Emily M. Hawes et al.   THROMBOSIS AND HAEMOSTASIS

Effects of storage time and temperature on coagulation tests and factors in fresh plasma

(2014) Limin Feng et al.   Scientific Reports

Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study

(2013) C. H. Miller et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels

(2013) E. M. Hawes et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon Resonance

(2013) Kenneth B. Lewis et al.   PLoS One

Mixing Tests: Diagnostic Aides in the Investigation of Prolonged Prothrombin Times and Activated Partial Thromboplastin Times

(2013) Daniel Orellana et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

External Quality Assessment of Factor VIII Inhibitor Assays

(2013) Emmanuel Favaloro et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Problems and Solutions in Laboratory Testing for Hemophilia

(2013) Piet Meijer et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors

(2013) Geoffrey W. Kershaw et al.   THROMBOSIS RESEARCH

The Effect of Dabigatran on Select Specialty Coagulation Assays

(2012) Dorothy M. Adcock et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients

(2012) S. F. J. Whelan et al.   BLOOD

Guidelines on the investigation and management of antiphospholipid syndrome

(2012) David Keeling et al.   BRITISH JOURNAL OF HAEMATOLOGY

More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance

(2012) E. Santagostino   HAEMOPHILIA

Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance

(2012) C. H. MILLER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction

(2012) M. DARDIKH et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Laboratory identification of factor inhibitors: an update

(2012) Geoffrey Kershaw et al.   PATHOLOGY

Acquired Functional Coagulation Inhibitors: Review on Epidemiology, Results of a Wet-Workshop on Laboratory Detection, and Implications for Quality of Inhibitor Diagnosis

(2012) Myriam Dardikh et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Quality Standards for Sample Processing, Transportation, and Storage in Hemostasis Testing

(2012) Dorothy Adcock Funk et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

The principal results of the International Immune Tolerance Study: a randomized dose comparison

(2011) C. R. M. Hay et al.   BLOOD

Development of a new modified Bethesda method for coagulation inhibitors: the Osaka modified Bethesda method

(2011) Sumiko Torita et al.   BLOOD COAGULATION & FIBRINOLYSIS

Parallel use of by-passing agents in haemophilia with inhibitors: a critical review

(2011) Jørgen Ingerslev et al.   BRITISH JOURNAL OF HAEMATOLOGY

The factor VIII inhibitor assays can be standardized: results of a workshop

(2011) B. VERBRUGGEN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The between-Laboratory Variation of Factor VIII Inhibitor Testing: The Experience of the External Quality Assessment Program of the ECAT Foundation

(2010) Piet Meijer et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Interlaboratory Variation in Factor VIII:C Inhibitor Assay Results Is Sufficient to Influence Patient Management: Data from the UK National Quality External Assessment Scheme for Blood Coagulation

(2010) Steve Kitchen et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Laboratory Identification of Factor Inhibitors: The Perspective of a Large Tertiary Hemophilia Center

(2010) Geoffrey Kershaw et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Laboratory Assessment of Factor VIII Inhibitor Titer

(2009) Ellinor I.B. Peerschke et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Quantitation of anti-factor VIII antibodies in human plasma

(2009) J. Krudysz-Amblo et al.   BLOOD

Diagnosis and quantification of factor VIII inhibitors

(2009) B. VERBRUGGEN   HAEMOPHILIA

Laboratory performance in the World Federation of Hemophilia EQA programme, 2003-2008

(2009) I. JENNINGS et al.   HAEMOPHILIA

The Prevalence of Bleeding Disorders Among Healthy Pediatric Patients With Abnormal Preprocedural Coagulation Studies

(2009) Peter H. Shaw et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Quality Control in Coagulation Testing

(2008) Mario Plebani et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Simultaneous detection and epitope mapping of anti-factor VIII antibodies

(2008) Priscilla Lapalud et al.   THROMBOSIS AND HAEMOSTASIS